Propel Bio Management as of March 31, 2026
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 38 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Plains Gp Hldgs Ltd Partnr Int A (PAGP) | 19.0 | $30M | 1.3M | 23.72 | |
| Achieve Life Sciences (ACHV) | 7.2 | $11M | 3.8M | 3.00 | |
| Phathom Pharmaceuticals (PHAT) | 5.9 | $9.4M | 841k | 11.12 | |
| Delcath Sys Com New (DCTH) | 5.8 | $9.2M | 980k | 9.35 | |
| Corcept Therapeutics Incorporated (CORT) | 3.8 | $6.0M | 148k | 40.74 | |
| Abeona Therapeutics Com New (ABEO) | 3.8 | $6.0M | 1.3M | 4.52 | |
| Vor Biopharma Com New (VOR) | 3.5 | $5.6M | 315k | 17.76 | |
| Kyverna Therapeutics (KYTX) | 3.5 | $5.6M | 644k | 8.67 | |
| Milestone Pharmaceuticals (MIST) | 3.2 | $5.1M | 4.1M | 1.23 | |
| Celldex Therapeutics Com New (CLDX) | 2.6 | $4.1M | 131k | 31.48 | |
| Compass Pathways Sponsored Ads (CMPS) | 2.6 | $4.1M | 742k | 5.55 | |
| Miragen Therapeutics (VRDN) | 2.6 | $4.1M | 210k | 19.45 | |
| Inventiva Sa Ads (IVA) | 2.5 | $4.0M | 725k | 5.51 | |
| Sab Biotherapeutics Com New (SABS) | 2.4 | $3.9M | 1.0M | 3.84 | |
| Health Sciences Acq Corp 2 (OBIO) | 2.4 | $3.8M | 897k | 4.27 | |
| 4d Molecular Therapeutics In (FDMT) | 2.3 | $3.6M | 380k | 9.41 | |
| Oculis Holding Ordinary Shares (OCS) | 2.1 | $3.3M | 122k | 26.83 | |
| Ocular Therapeutix (OCUL) | 2.0 | $3.2M | 382k | 8.44 | |
| Upstream Bio (UPB) | 2.0 | $3.1M | 342k | 9.07 | |
| Aquestive Therapeutics (AQST) | 1.9 | $3.0M | 711k | 4.15 | |
| Eyepoint Com New (EYPT) | 1.8 | $2.8M | 216k | 12.92 | |
| Trevi Therapeutics (TRVI) | 1.7 | $2.6M | 224k | 11.83 | |
| Zevra Therapeutics Com New (ZVRA) | 1.7 | $2.6M | 282k | 9.35 | |
| Immunic (IMUX) | 1.7 | $2.6M | 2.3M | 1.12 | |
| Coherus Biosciences (CHRS) | 1.5 | $2.4M | 1.4M | 1.70 | |
| Ovid Therapeutics (OVID) | 1.3 | $2.0M | 922k | 2.21 | |
| Palisade Bio (PALI) | 1.3 | $2.0M | 1.1M | 1.79 | |
| Kalaris Therapeutics (KLRS) | 1.1 | $1.7M | 296k | 5.82 | |
| Uniqure Nv SHS (QURE) | 1.1 | $1.7M | 105k | 16.35 | |
| Athira Pharma (LONA) | 0.9 | $1.5M | 149k | 10.02 | |
| Nuvation Bio Com Cl A (NUVB) | 0.9 | $1.4M | 329k | 4.29 | |
| Maze Therapeatics (MAZE) | 0.8 | $1.3M | 44k | 29.85 | |
| Evommune Com Shs (EVMN) | 0.8 | $1.3M | 56k | 22.99 | |
| Corvus Pharmaceuticals (CRVS) | 0.8 | $1.3M | 86k | 14.58 | |
| Aldeyra Therapeutics (ALDX) | 0.8 | $1.2M | 731k | 1.69 | |
| Artiva Biotherapeutics (ARTV) | 0.6 | $950k | 146k | 6.49 | |
| Connect Biopharma Hldgs SHS (CNTB) | 0.3 | $554k | 210k | 2.64 | |
| Satellos Bioscience | 0.0 | $57k | 10k | 5.63 |
